Entinostat

Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.[1]

Entinostat

Names
IUPAC name Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
Other names SNDX-275; MS-275
Identifiers
CAS Number	209783-80-2 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:132082 N
ChEMBL	ChEMBL27759 N
ChemSpider	4111 N
ECHA InfoCard	100.158.999
IUPHAR/BPS	7007
KEGG	D09338 Y
PubChem CID	4261
UNII	1ZNY4FKK9H Y
CompTox Dashboard (EPA)	DTXSID0041068
InChI InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) N Key: INVTYAOGFAGBOE-UHFFFAOYSA-N N InChI=1/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26) Key: INVTYAOGFAGBOE-UHFFFAOYAU
SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
Properties
Chemical formula	C21H20N4O3
Molar mass	376.4085 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Entinostat inhibits class I HDAC1 and HDAC3 with IC₅₀ of 0.51 μM and 1.7 μM, respectively.[2]

Syndax pharmaceuticals currently holds the rights to Entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.[3]